secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009236
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023
--------------------------------------------------------------------------------

- Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.
- Net loss $35.7M vs $28.3M in 2021; R&D expenses $22.5M (+31% YoY).
- TPST-1120 Phase 1 showed 30% ORR at highest doses in checkpoint-inhibitor non-responsive patients.
- Randomized Phase 1b/2 study in first-line HCC fully enrolled; initial data expected H1 2023.
- TPST-1495 Phase 1 dose escalation ongoing; initial data expected by mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/tpst-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer